Original researchRandomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models
References (39)
- et al.
Diagnosis and management of rhinitis: Complete guidelines of the joint Task Force on Practice Parameters in Allergy, Asthma and Immunology
Ann Allergy Asthma Immunol
(1998) - et al.
Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug
Jpn J Pharmacol
(2002) - et al.
Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells
Ann Allergy Asthma Immunol
(1997) Use of nasal steroids in managing allergic rhinitis
J Allergy Clin Immunol
(1999)- et al.
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge
Clin Ther
(2002) - et al.
Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid
Ann Allergy Asthma Immunol
(2002) - et al.
Effects of fexofenadine on the early response to nasal allergen challenge
Ann Allergy Asthma Immunol
(2002) - et al.
Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge
Ann Allergy Asthma Immunol
(2001) - et al.
Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions
J Allergy Clin Immunol
(1999) - et al.
Antiallergic activity of H1-receptor antagonists assessed by nasal challenge
J Allergy Clin Immunol
(1988)
Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis
Ann Allergy Asthma Immunol
Onset of action of aqueous beclomethasone dipropionate nasal spray in seasonal allergic rhinitis
Clin Ther
Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis
J Allergy Clin Immunol
A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model
Clin Ther
A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis
Clin Ther
Animal model for the absorption of lipophilic substances from tear fluid by the epithelium of the nasolacrimal ducts
Invest Ophthalmol Vis Sci
Cited by (55)
Conventional medications for the treatment of allergic rhinitis and conjunctivitis
2022, Allergic and Immunologic Diseases: A Practical Guide to the Evaluation, Diagnosis and Management of Allergic and Immunologic DiseasesTear cytokine levels in allergic rhinitis without ocular symptoms
2019, Canadian Journal of OphthalmologyCitation Excerpt :Some treatments that have started to utilize this concept include using wraparound spectacles to improve the symptoms of seasonal allergic rhinitis28 and utilizing intranasal corticosteroids and nasal filters to manage the ocular symptoms of allergic rhinoconjunctivitis.29–35 The interrelatedness of allergic rhinitis and rhinoconjunctivitis may tempt the clinician to consider monotherapy (treating either the nasal or the ocular inflammation) in the hope that the less severely affected organ will respond also, but we advise caution in this matter, as the results obtained thus far are variable.32,36,37 Although we are limited by our small sample size, no other previously published work has demonstrated increased levels of inflammatory cytokines in the tear film of patients with isolated allergic rhinitis without evidence of allergic conjunctivitis.
Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis
2013, Pediatrics and NeonatologyCitation Excerpt :FP delivered through the intranasal route has an absolute bioavailability average of <2%, and MFM shows extremely low bioavailability (<1%) in plasma.20,21 Thus, nasal sprays may fail to control ocular symptoms if they cannot induce any meaningful movement of allergens, their mediators, or antiallergy drugs from the nasal cavity to the ocular surface.22 We found MFM sprays to be significantly more effective than FP sprays for relieving nasal symptoms, as evidenced by the differences in TSS between the two groups.
Nasal-Ocular Reflexes and Their Role in the Management of Allergic Rhinoconjunctivitis with Intranasal Steroids
2011, World Allergy Organization JournalCitation Excerpt :Some authors have suggested that intranasal steroids increase drainage in inflamed nasolacrimal ducts, thereby reducing conjunctival exposure to allergens and inflammatory mediators. However, duct patency has been found to be maintained in subjects who had symptomatic allergic responses after ocular challenge36. It has also been suggested that intranasal steroids might travel through the nasolacrimal duct, exerting their anti-inflammatory effect directly on the conjunctiva.
Efficacy of intranasal corticosteroids on the ocular symptoms of allergic rhinitis
2010, Revue Francaise d'AllergologieBepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge
2010, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :Using both nasal allergen challenge and CAC may have been more representative of the nasal and ocular signs and symptoms experienced in the environment. It has been previously shown that both nasal allergen challenge and CAC induce similar patterns of allergic response and effectiveness of clinical treatment for nasal and ocular allergic reactions.4 Therefore, the nasal symptom results using the CAC method can be considered to mimic the nasal symptoms of a nasal allergen challenge, which in the present CAC studies satisfactorily induced nonocular (particularly nasal) allergic symptoms and provided evidence of effective improvement after treatment with 1.5% bepotastine besilate.